Phathom Pharmaceuticals (PHAT) EBIAT (2022 - 2025)
Historic EBIAT for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to -$30.0 million.
- Phathom Pharmaceuticals' EBIAT rose 6497.54% to -$30.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$274.6 million, marking a year-over-year increase of 1911.8%. This contributed to the annual value of -$334.3 million for FY2024, which is 6584.29% down from last year.
- As of Q3 2025, Phathom Pharmaceuticals' EBIAT stood at -$30.0 million, which was up 6497.54% from -$75.8 million recorded in Q2 2025.
- In the past 5 years, Phathom Pharmaceuticals' EBIAT ranged from a high of -$30.0 million in Q3 2025 and a low of -$94.3 million during Q1 2025
- For the 4-year period, Phathom Pharmaceuticals' EBIAT averaged around -$62.2 million, with its median value being -$55.0 million (2022).
- As far as peak fluctuations go, Phathom Pharmaceuticals' EBIAT tumbled by 12322.96% in 2024, and later surged by 6497.54% in 2025.
- Over the past 4 years, Phathom Pharmaceuticals' EBIAT (Quarter) stood at -$55.0 million in 2022, then tumbled by 44.55% to -$79.6 million in 2023, then increased by 6.43% to -$74.5 million in 2024, then skyrocketed by 59.74% to -$30.0 million in 2025.
- Its last three reported values are -$30.0 million in Q3 2025, -$75.8 million for Q2 2025, and -$94.3 million during Q1 2025.